JPA version - The Lancet

JPA version - The Lancet

P-copyright license-v3/2016 JOURNAL OWNER (hereinafter the “Journal”) LICENSE AGREEMENT PLEASE PROVIDE US WITH THE FOLLOWING INFORMATION, REVIEW OUR ...

37KB Sizes 0 Downloads 3 Views

Recommend Documents

Lancet Psychiatry - The Lancet
May 17, 2016 - Robin L Carhart-Harris, Mark Bolstridge, James Rucker*, Camilla M J ...... Robert Sullivan (Meridian West

Supplementary appendix - The Lancet
6 days ago - Very High HDI. (n=52). Afghanistan. Bangladesh. Albania. Argentina. Angola. Bhutan. Algeria. Australia. Ben

Supplementary appendix - The Lancet
Klinik IV, Hämatologie/ Onkologie, Justus-Liebig-. Universität Gießen ... Herrenberger/ Dr. Keitel-Wittig/ Dr. Kirsch

Supplementary appendix - The Lancet
Jun 16, 2014 - David Smith, TheClatterbridge Cancer Centre (Wirral); Dr. Alan ... (Glasgow); Dr. Jonathan Wadsley, Westo

Supplementary appendix - The Lancet
Oct 20, 2017 - Fakultni Nemocnice Brno, Brno: Principal investigator: Stanislav Vohanka; ... Principal investigator: Bel

Supplementary appendix - The Lancet
Sep 12, 2017 - Linus. Jonsson. Richard. Josephson. Rudolf. Kaaks. Amanda. Kamali. Eva. Kantelhardt. Etienne .... Sebasti

Supplementary appendix - The Lancet
TRILOGY manuscript supplement. 14 August 2016. Page 1 of 17. Supplementary material. Title: Triple therapy in a single i

Supplementary appendix - The Lancet
09.07.2015 - Bayreuth. Klinikum Bayreuth Kinderklinik Preuschwitzerstr. Prof. Dr. med. .... Dr. von Hauner'sches Kinders

Supplementary appendix - The Lancet
2 days ago - ... Benoit Varenne, Stéphane Verguet, Russell Viner, Jane Waldfogel, ... Kristine West, Jordan Worthington

Supplementary appendix - The Lancet
Tobacco content in video games: 1994–2011. Lancet Oncol ... City Interactive S. Management Board and Supervisory Board

P-copyright license-v3/2016 JOURNAL OWNER (hereinafter the “Journal”)

LICENSE AGREEMENT PLEASE PROVIDE US WITH THE FOLLOWING INFORMATION, REVIEW OUR POLICIES AND THE LICENSE AGREEMENT, AND INDICATE YOUR ACCEPTANCE OF THE TERMS

Manuscript number/article number (to be found in acknowledgement email you have received): Article title: Corresponding author: To be published in the journal: Your organization:

YOUR STATUS (PLEASE MARK ALL THAT APPLY) I am the sole author of the manuscript Please indicate which of the below applies to you: I am a UK, Canadian or Australian Government employee and Crown Copyright is asserted I am a US Government employee and the Article is public domain and therefore the ‘License of publishing rights’ clause does not apply I am a contractor of the US Government under contract number: ……………….………………………….……………………… None of the above

I am one author signing on behalf of all co-authors of the manuscript Please indicate which of the below applies to you: We are all US Government employees and the Article is public domain and therefore the ‘License of publishing rights’ clause does not apply I am a US Government employee but some of my co-authors are not I am not a US Government employee but some of my co-authors are The work was performed by contractors of the US Government under contract number: ...………………….…………..………... All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted None of the above

I am signing as an authorized representative and on behalf of my employer Name and job title of licensor if different from corresponding author: ...................................................................................................... Please indicate which of the below applies to you: The Article is authored by US Government employees and the Article is public domain and therefore the ‘License of publishing rights’ clause does not apply The work was performed by contractors of the US Government under contract number: ……………………………………….. The Article is authored by UK, Canadian or Australian Government employees and Crown Copyright is asserted My employer is the owner of the copyright in the Article Organization (please use the full name of the organization as it should appear in the copyright notice): ……………………………………... None of the above

DATA PROTECTION & PRIVACY I understand that staff of the journal owner and the publisher and its affiliated companies worldwide will be contacting me concerning the publishing of the Article and occasionally for marketing purposes (unless, with respect to such marketing, I tick the box below). I do not wish to receive news, promotions and special offers about products and services of the journal owner and the publisher and its affiliated companies worldwide Please tick one or more of the above boxes (as appropriate), review the License Agreement and then sign and date the License Agreement in black ink. Signed: ______________________________________

Name printed: ___________________________________________

Title and Company (if employer representative): _________________________________________________________ Date: _______________________________________ Please return the completed and signed original of this form by mail or fax, or by e-mailing a scanned copy of the signed original, retaining a copy for your files, to: [Elsevier Return Address]

P-copyright license-v3/2016

LICENSE AGREEMENT License of publishing rights I hereby grant to the Journal an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the “Article”) in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties. Supplemental Materials With respect to Supplemental Materials that I wish to make accessible through a link in the Article or on a site or through a service of the Journal, the Journal shall be entitled to publish, post, reformat, index, archive, make available and link to such Supplemental Materials on a non-exclusive basis in all forms and media (whether now known or later developed), and permit others to do so. “Supplemental Materials” shall mean additional materials that are not an intrinsic part of the Article, including but not limited to experimental data, e-components, encodings and software, and enhanced graphical, illustrative, video and audio material. Scholarly communication rights I understand that I retain the copyright in the Article and that no rights in patents, trademarks or other intellectual property rights are transferred to the Journal. As the author of the Article, I understand that I shall have the same rights to reuse the Article as those allowed to third party users (and the Journal) of the Article under the CC-BY License. User rights The publisher will apply the Creative Commons Attribution-4.0 International License (CC BY) to the Article where it publishes the Article in the journal on its online platforms on an Open Access basis. For further information, see http://www.elsevier.com/about/open-access/open-accessoptions. The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at https://creativecommons.org/licenses/by/4.0/. Reversion of rights Articles may sometimes be accepted for publication but later rejected in the publication process, even in some cases after public posting in “Articles in Press” form, in which case all rights will revert to the author (see http://www.elsevier.com/locate/withdrawalpolicy). Revisions and addenda I understand that no revisions, additional terms or addenda to this License Agreement can be accepted without the Journal’s express written consent. I understand that this License Agreement supersedes any previous agreements I have entered into with the Journal in relation to the Article from the date hereof. Copyright Notice The publisher shall publish and distribute the Article with the appropriate copyright notice. Author Representations/Ethics and Disclosure/Sanctions I affirm the Author Representations noted below, and confirm that I have reviewed and complied with the relevant Instructions to Authors, Ethics in Publishing policy, Declarations of Interest disclosure and information for authors from countries affected by sanctions (Iran, Cuba, Sudan, Burma, Syria, or Crimea). Please note that some journals may require that all co-authors sign and submit Declarations of Interest disclosure forms. I am also aware of the publisher’s policies with respect to retractions and withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). For further information see the publishing ethics page at http://www.elsevier.com/publishingethics and the journal home page. For further information on sanctions, see https://www.elsevier.com/trade-sanctions Author Representations • The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published. • The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal. • The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter. • I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials. • Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses and, if my or any of my coauthors’ institution has a policy that might restrict my ability to grant the rights required by this License Agreement (taking into account the Scholarly communication rights permitted hereunder), a written waiver of that policy has been obtained. • If I and/or any of my co-authors reside in Iran, Cuba, Sudan, Burma, Syria, or Crimea, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government. • If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher’s policies relating to the use of such images or personal information. See http://www.elsevier.com/patientphotographs for further information. Any software contained in the Supplemental Materials is free from viruses, contaminants or worms. • If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so. For information on the publisher’s copyright and access policies, please see http://www.elsevier.com/copyright.